Intervention Protocol

You have free access to this content

The impact of biological interventions for ulcerative colitis on health-related quality of life

  1. Katie LeBlanc1,*,
  2. Mahmoud Mosli2,3,
  3. Kenneth A Baker4,
  4. John K MacDonald4

Editorial Group: Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group

Published Online: 6 JUN 2013

DOI: 10.1002/14651858.CD008655.pub2


How to Cite

LeBlanc K, Mosli M, Baker KA, MacDonald JK. The impact of biological interventions for ulcerative colitis on health-related quality of life (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD008655. DOI: 10.1002/14651858.CD008655.pub2.

Author Information

  1. 1

    Robarts Research Institute, c/o Robarts Clinical Trials, London, Ontario, Canada

  2. 2

    London Health Sciences Centre, Victoria Hospital, London, Ontario, Canada

  3. 3

    King Abdulaziz University, King Abdulaziz University Hospital, Jeddah, Saudi Arabia

  4. 4

    Robarts Research Institute, Robarts Clinical Trials, London, Ontario, Canada

*Katie LeBlanc, c/o Robarts Clinical Trials, Robarts Research Institute, PO Box 5015, 100 Perth Drive, London, Ontario, N6A 5K8, Canada. cathy.leblanc@utoronto.ca.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 6 JUN 2013

SEARCH

References

Additional references

Bernklev 2005
Bernklev 2006
Boonen 2002
Feagan 1999
  • Feagan BG. Review article: economic issues in Crohn's disease--assessing the effects of new treatments on health-related quality of life. Alimentary Pharmacology and Therapeutics 1999;13(Suppl 4):29-37; discussion 38.
Feagan 2007
  • Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. American Journal of Gastroenterology 2007;102(4):794-802.
    Direct Link:
Guyatt 1989
  • Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96(3):804-10.
Guyatt 2008
  • Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
Ha 2010
  • Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand?. Current Gastroenterology Reports 2010;12(6):471-8.
Higgins 2003
Higgins 2011
  • Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Irvine 1994
  • Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106(2):287-96.
Irvine 1996
  • Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory BowelDisease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. American Journal of Gastroenterology 1996;91(8):1571-8.
Irvine 2008
Janke 2004
  • Janke KH, Raible A, Bauer M, Clemens P, Meisner C, Häuser W, et al. Questions on life satisfaction (FLZM) in inflammatory bowel disease. International Journal of Colorectal Disease 2004;19(4):343-53.
Janke 2005
Konig 2002
  • Konig HH, Ulsofer A, Gregor M, von Tirpiz C, Reinshagen M, Adler G, Leidl R. Validation of the EuroQoL questionnaire in patients with inflammatory bowel disease.. European Journal of Gastroenterology and Hepatology 2002;14(11):1205-15.
Marri 2005
Petrak 2001
  • Petrak F, Hardt J, Clement T, Börner N, Egle UT, Hoffmann SO. Impaired health-related quality of life in inflammatory bowel diseases: psychosocial impact and coping styles in a national German sample. Scandinavian Journal of Gastroenterology 2001;36(4):375-82.
Reinisch 2007
Schünemann 2011
  • Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Vogelaar 2009
  • Vogelaar L, Spijker AV, van der Woude CJ. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clinical and Experimental Gastroenterology 2009;2:101-9.
Ware 1992